The role of natural killer cells in hematopoietic stem cell transplantation

References

• Orange JS. Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol. 2006;6:399–409.
   PubMed Web of Science ®Google Scholar
• Etzioni A, Eidenschenk C, Katz R, Beck R, Casanova JL, Pollack S. Fatal varicella associated with selective natural killer cell deficiency. J Pediatr. 2005;146:423–5.
   PubMedGoogle Scholar
• Eidenschenk C, Jouanguy E, Alcaıs A, Mention JJ, Pasquier B, Fleckenstein IM, . Familial NK cell deficiency associated with impaired IL-2-and IL-15-dependent survival of lymphocytes. J Immunol. 2006;177:8835–43.
   Google Scholar
• Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol. 1995;7:704–10.
   PubMed Web of Science ®Google Scholar
• Chang CC, Ferrone S. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Semin Cancer Biol. 2006;16:383–92.
   Google Scholar
• Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol. 2009;9:568–80.
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood. 2008; 112:461–9.
   PubMed Web of Science ®Google Scholar
• Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med. 1989;169:2233–8.
   PubMed Web of Science ®Google Scholar
• Ritz J, Schmidt RE, Michon J, Hercend T, Schlossman SF. Characterization of functional surface structures on human natural killer cells. Adv Immunol. 1988;42:181–211.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, . CD56bright natural killer cells are present in human lymph nodes and are activated by T cell derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101:3052–7.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, . Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood. 2001;97:3146–51.
   PubMed Web of Science ®Google Scholar
• Romagnani C, Juelke K, Falco M, Morandi B, D'Agostino A, Costa R, . CD56brightCD16-killer Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol. 2007;178: 4947–55.
   PubMed Web of Science ®Google Scholar
• Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, . CD56bright human NK cells differentiate into CD56dim cells: Role of contact with peripheral fibroblasts. J Immunol. 2007;179:89–94.
   PubMed Web of Science ®Google Scholar
• Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. 2006;214:56–72.
   PubMed Web of Science ®Google Scholar
• Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20:123–37.
   PubMed Web of Science ®Google Scholar
• Di Santo JP, Vosshenrich CAJ. Bone marrow versus thymic pathways of natural killer cell development. Immunol Rev. 2006;214:35–46.
   Google Scholar
• Vales-Gomez M, Reyburn H, Strominger J. Molecular analyses of the interactions between human NK receptors and their HLA ligands. Hum Immunol. 2000;61:28–38.
   PubMedGoogle Scholar
• Lopez-Botet M, Bellon T. Natural killer cell activation and inhibition by receptors for MHC class I. Curr Opin Immunol. 1999;11:301–7.
   PubMed Web of Science ®Google Scholar
• Lopez-Botet M, Bellon T, Llano M, Navarro F, Garcıa P, de Miguel M. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol. 2000; 61:7–17.
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell receptors. Annu Rev lmmunol. 1998;16: 359–93.
   PubMed Web of Science ®Google Scholar
• Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, . Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol. 2001;31:1076–86.
   PubMed Web of Science ®Google Scholar
• Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, . ULBPs, novel MHC class I-related bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123–33.
   PubMed Web of Science ®Google Scholar
• Bauer S, Groh V, Wu J, Steinle A, Phillips JA, Lanier LL, . Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727–9.
   PubMed Web of Science ®Google Scholar
• Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, . Ligands for natural killer cell– activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood. 2005;105:3615–22.
   PubMed Web of Science ®Google Scholar
• Lebbink RJ, de Ruiter T, Adelmeijer J, Brenkman AB, van Helvoort JM, Koch M, . Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med. 2006;203:1419–25.
   Google Scholar
• Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, . Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 2001;409:1055–60.
   PubMed Web of Science ®Google Scholar
• Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, . Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007;27:965–74.
   PubMed Web of Science ®Google Scholar
• Horowitz A, Riley EM. Activation of human NK cells by malaria-infected red blood cells. Methods Mol Biol. 2010; 612:429–46.
   Google Scholar
• Cagnano E, Hershkovitz O, Zilka A, Bar-Ilan A, Golder A, Sion-Vardy N, . Expression of ligands to NKp46 in benign and malignant melanocytes. J Invest Dermatol. 2008;128:972–9.
   Google Scholar
• Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, . Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One. 2008;3:e2150.
   Google Scholar
• Bottino C, Biassoni R, Millo R, Moretta L, Moretta A. The human natural cytotoxicity receptors (NCR) that induce HLA Class I-independent NK cell triggering. Hum Immunol. 2000;61:1–6.
   PubMed Web of Science ®Google Scholar
• Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, . Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99:3661–7.
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK recognition. Immunol Today. 1990;11:237–44.
   PubMedGoogle Scholar
• Blery M, Olcese L, Vivier E. Early signaling via inhibitory and activating NK receptors. Hum Immunol. 2000;61: 51–64.
   Google Scholar
• Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225–74.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, . Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–100.
   PubMed Web of Science ®Google Scholar
• Yokoyama WM. Specific and non-specific natural killer cell responses to viral infection. Adv Exp Med Biol. 2005;560: 57–61.
   Google Scholar
• Torelli GF, Guarini A, Palmieri G, Breccia M, Vitale A, Santoni A, . Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. Br J Haematol. 2002;116:299–307.
   PubMed Web of Science ®Google Scholar
• Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, Tyan D, . Genetic control of human NK cell repertoire. J Immunol. 2002;169:239–47.
   PubMed Web of Science ®Google Scholar
• Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D, . Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol. 2002;168:2307–15.
   PubMed Web of Science ®Google Scholar
• Uhrberg M. Shaping the human NK cell repertoire: an epigenetic glance at KIR gene regulation. Mol Immunol. 2005;42:471–5.
   Google Scholar
• Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol. 2001;19:291–330.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Held W, Correa I, Dorfman J, Wu M-F, Corral L. Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Immunol Rev. 1997;155:41–52.
   Google Scholar
• Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, . Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739–51.
   PubMed Web of Science ®Google Scholar
• Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, . Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25:331–42.
   PubMed Web of Science ®Google Scholar
• Yokoyama WM, Kim S. Licencing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev. 2006;214:143–54.
   Google Scholar
• Parham P. Taking license with natural killer cell maturation and repertoire development. Immunol Rev. 2006;214: 155–60.
   PubMed Web of Science ®Google Scholar
• Vitale M, Zimmer J, Castriconi R, Hanau D, Donato L, Bottino C, . Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells. Blood. 2002; 99:1723–9.
   Google Scholar
• Zimmer J, Donato L, Hanau D, Cazenave JP, Tongio MM, Moretta A, . Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med. 1998;187: 117–22.
   Google Scholar
• Moins-Teisserenc HT, Gadola SD, Cella M, Dunbar PR, Exley A, Blake N, . Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet. 1999;354:1598–603.
   PubMedGoogle Scholar
• Zimmer J, Donato L, Hanau D, Cazenave JP, Moretta A, Tongio MM, . Inefficient protection of human TAP-deficient fibroblasts from autologous NK cell-mediated lysis by cytokines inducing HLA class I expression. Eur J Immunol. 1999;29:1286–91.
   Google Scholar
• Sykes M, Harty MW, Karlhofer FM, Pearson DA, Szot G, Yokoyama W. Hematopoietic cells and radioresistant host elements influence natural killer cell differentiation. J Exp Med. 1993;178:223–9.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ohdan H, O'Manilay J, Sykes M. NK cell tolerance in mixed allogeneic chimeras. J Imunnol. 2003;170: 5398–405.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009;106:1915–9.
   PubMed Web of Science ®Google Scholar
• Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature. 2009;457:557–61.
   PubMed Web of Science ®Google Scholar
• Sun JC, Lanier LL. Natural killer cells remember: An evolutionary bridge between innate and adaptive immunity? Eur J Immunol. 2009;39:2059–64.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, . Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339: 1186–93.
   PubMed Web of Science ®Google Scholar
• Reisner Y, Martelli MF. Transplantation tolerance induced by ‘mega dose’ CD34+ cell transplants. Exp Hematol. 2000; 28:119–27.
   Google Scholar
• Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, . Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–9.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, . Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110:433–40.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T, . NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2008;40:84–90.
   PubMed Web of Science ®Google Scholar
• Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert M, Liu J, . Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–5.
   PubMed Web of Science ®Google Scholar
• Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, . A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112:3574–81.
   PubMed Web of Science ®Google Scholar
• Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, . Analysis of the receptor-ligand interactions in the natural killer–mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood. 2005;105:2066–73.
   PubMed Web of Science ®Google Scholar
• Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, . Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172:644–50.
   PubMed Web of Science ®Google Scholar
• Pfeiffer M, Schumm M, Feuchtinger T, Dietz K, Handgretinger R, Lang P. Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia. Br J Haematol. 2007;138:97–100.
   Google Scholar
• Cooper MA, Bush JE, Fehniger TA, Van Deusen JB, Waite RE, Liu Y, . In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002; 100:3633–8.
   PubMed Web of Science ®Google Scholar
• Miller J, Soignier Y, Panoskaltsis-Mortari A, McNearney S, Yun GH, Fautsch S, . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood. 2005;105:3051–7.
   Google Scholar
• Velardi A, Ruggeri L, Mancusi A, Burchielli E, Perruccio K, Aversa F, . Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Semin Immunopathol. 2008;30:489–93.
   Google Scholar
• Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, . Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009;113:3119–29.
   PubMed Web of Science ®Google Scholar
• Yu J, Venstrom JM, Liu X-R, Pring J, Hasan RS, O'Reilly RJ, . Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell–depleted allogeneic hematopoietic cell transplantation. Blood. 2009;113:3875–84.
   PubMed Web of Science ®Google Scholar
• Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, . Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814–9.
   PubMed Web of Science ®Google Scholar
• Davies SM, Ruggieri L, De For T, Wagner JE, Weisdorf DJ, Miller J, . Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood. 2002;100:3825–7.
   PubMed Web of Science ®Google Scholar
• Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, . The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transpl. 2006;12:876–84.
   PubMed Web of Science ®Google Scholar
• Morishima Y, Yabe T, Matsuo K, Kashiwase K, Inoko H, Saji H, . Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell–replete marrow from an unrelated donor. Biol Blood Marrow Transplant. 2007;13:315–28.
   PubMedGoogle Scholar
• Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura-Ishii S, Tanaka H, . Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell–replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant. 2008;14:75–87.
   PubMed Web of Science ®Google Scholar
• Hsu K, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon J-D, . KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2006;12:828–36.
   PubMed Web of Science ®Google Scholar
• Miller JS, Cooley S, Parham P, Farag SS, Verneris M, McQueen K, . Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109:5058–61.
   PubMed Web of Science ®Google Scholar
• Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, . Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878–84.
   PubMed Web of Science ®Google Scholar
• Clausen J, Kircher B, Auberger J, Schumacher P, Ulmer H, Hetzenauer G, . The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. Biol Blood Marrow Transplant. 2010;16:273–80.
   Google Scholar
• Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF, . The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood. 2004;103:1521–6.
   Google Scholar
• McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol. 2007;68:309–23.
   PubMed Web of Science ®Google Scholar
• Bjorklund AT, Schaffer M, Fauriat C, Ringden O, Remberger M, Hammarstedt C, . NK cells expressing inhibitory KIR for non–self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood. 2010;115: 2686–94.
   Google Scholar
• Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA. Inhibitory KIR–HLA receptor–ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer. 2007; 97:539 –42.
   Google Scholar
• Stern M, Paulussen M, Rischewski J, Tichelli A, Gratwohl A. Missing ligand model in autologous stem cell transplantation. Br J Cancer. 2008;98:852–3.
   Google Scholar
• Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung I, . KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res. 2009;15:7330–4.
   PubMed Web of Science ®Google Scholar
• Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010;235: 267–85.
   PubMed Web of Science ®Google Scholar
• Giebel S, Nowak I, Dziaczkowska J, Czerw T, Wojnar J, Krawczyk-Kulis M, . Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2009;83: 343–56.
   Google Scholar
• Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le C, . Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113:726–32.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Imai K, Morishita Y, Hayashi I, Kusunoki Y, Nakachi K. Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res. 2006; 66:563–70.
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795–9.
   PubMed Web of Science ®Google Scholar
• Furue H, Kumimoto H, Matsuo K, Suzuki T, Hasegawa Y, Shinoda M, . Opposite impact of NKG2D genotype by lifestyle exposure to risk of aerodigestive tract cancer among Japanese. Int J Cancer. 2008;123:181–6.
   PubMed Web of Science ®Google Scholar
• Espinoza JL, Takami A, Onizuka M, Sao H, Akiyama H, Miyamura K, . NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica. 2009;94:1427–34.
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, . Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010;115:3437–46.
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Schwerdtfeger R, Martin H, Frank K-H, Theuser C, Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood. 2004;103:2860–1.
   PubMed Web of Science ®Google Scholar
• De Santis D, Bishara A, Witt CS, Nagler A, Brautbar C, Slavin S, . Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens. 2005;65:519–28.
   Google Scholar
• Schaffer M, Malmberg KL, Ringden O, Ljunggren HG, Remberger M. Increased infection-related mortality in KIR-ligand–mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation. 2004;78:1081–5.
   PubMedGoogle Scholar
• Beelen DW, Ottinger HD, Ferencik S, Elmaagacli A, Peceny R, Trenschel R, . Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2005;105:2594–600.
   PubMedGoogle Scholar
• Elmaagacli A, Ottinger H, Koldehoff M, Peceny R, Steckel N, Trenschel R, . Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation. 2005;79:1741–7.
   PubMed Web of Science ®Google Scholar
• Sobecks RM, Ball EJ, Maciejewski JP, Rybicki LA, Brown S, Kalaycio M, . Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant. 2007;39:417–24.
   PubMedGoogle Scholar